IL155992A0 - Pharmaceutical compositions for the oral delivery of pharmacologically active agents - Google Patents

Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Info

Publication number
IL155992A0
IL155992A0 IL15599201A IL15599201A IL155992A0 IL 155992 A0 IL155992 A0 IL 155992A0 IL 15599201 A IL15599201 A IL 15599201A IL 15599201 A IL15599201 A IL 15599201A IL 155992 A0 IL155992 A0 IL 155992A0
Authority
IL
Israel
Prior art keywords
pharmacologically active
active agents
pharmaceutical compositions
oral delivery
delivery
Prior art date
Application number
IL15599201A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL155992A0 publication Critical patent/IL155992A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15599201A 2000-12-06 2001-12-05 Pharmaceutical compositions for the oral delivery of pharmacologically active agents IL155992A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25172900P 2000-12-06 2000-12-06
PCT/EP2001/014294 WO2002045754A2 (fr) 2000-12-06 2001-12-05 Compositions pharmaceutiques utilisees dans l'administration orale de principes actifs sur le plan pharmacologique

Publications (1)

Publication Number Publication Date
IL155992A0 true IL155992A0 (en) 2003-12-23

Family

ID=22953160

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15599201A IL155992A0 (en) 2000-12-06 2001-12-05 Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IL155992A IL155992A (en) 2000-12-06 2003-05-19 Pharmacological preparations of pharmacologically active substances for oral administration

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155992A IL155992A (en) 2000-12-06 2003-05-19 Pharmacological preparations of pharmacologically active substances for oral administration

Country Status (27)

Country Link
US (1) US7049283B2 (fr)
EP (1) EP1341526B1 (fr)
JP (2) JP4898078B2 (fr)
KR (1) KR100847695B1 (fr)
CN (1) CN1304048C (fr)
AT (1) ATE513541T1 (fr)
AU (2) AU3454702A (fr)
BR (2) BRPI0115965B1 (fr)
CA (1) CA2436599C (fr)
CY (1) CY1112562T1 (fr)
CZ (1) CZ305418B6 (fr)
DK (1) DK1341526T3 (fr)
EC (1) ECSP034639A (fr)
ES (1) ES2367009T3 (fr)
HK (1) HK1059565A1 (fr)
HU (1) HU230632B1 (fr)
IL (2) IL155992A0 (fr)
MX (1) MXPA03005096A (fr)
NO (1) NO332936B1 (fr)
NZ (1) NZ526196A (fr)
PL (1) PL209703B1 (fr)
PT (1) PT1341526E (fr)
RU (1) RU2287999C2 (fr)
SI (1) SI1341526T1 (fr)
SK (1) SK287613B6 (fr)
WO (1) WO2002045754A2 (fr)
ZA (1) ZA200304295B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175390B1 (fr) * 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Sels disodiques, monohydrates et solvates ethanol pour liberer des agents actifs
BRPI0209748B1 (pt) * 2001-06-01 2015-11-24 Novartis Ag composição farmacêutica para administração oral compreendendo hormonio paratireoide(pth), e seu uso
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
PE20040724A1 (es) * 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
KR100857759B1 (ko) * 2003-03-17 2008-09-09 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
ES2330638T3 (es) * 2003-07-11 2009-12-14 Novartis Ag Composiciones farmaceuticas dosificadas en forma oral que contienen un agente de suministro en forma micronizada.
DK3260117T3 (da) * 2003-09-12 2019-07-01 Amgen Inc Hurtigt opløsende formulering, der omfatter cinacalcet-hcl
MXPA06013384A (es) * 2004-05-19 2007-03-01 Emisphere Tech Inc Formulaciones topicas de cromolin.
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
JP5175553B2 (ja) * 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
WO2007005995A2 (fr) * 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions pour administration par voie buccale de l'hormone de croissance humaine
RU2507196C2 (ru) 2005-09-19 2014-02-20 Эмисфире Текнолоджис, Инк. Кристаллические формы динатриевой соли n-(5-хлорсалицилоил)-8-аминокаприловой кислоты
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
US20080255048A1 (en) * 2005-11-17 2008-10-16 Moise Azria Pharmaceutical Composition
US7476405B2 (en) * 2006-02-23 2009-01-13 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
AU2007284801A1 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
CA2661521C (fr) * 2006-08-31 2016-04-12 Novartis Ag Compositions pharmaceutiques a hormone de croissance humaine pour delivrance par voie orale
CA2572004A1 (fr) * 2006-12-08 2008-06-08 Bernard Charles Sherman Comprimes renfermant de l'entacapone et de la crospovidone
ES2365648T3 (es) * 2007-03-02 2011-10-07 Novartis Ag Administración oral de una calcitonina.
US8022048B2 (en) 2007-11-02 2011-09-20 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
CN102123697B (zh) 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
CA2755068C (fr) * 2009-03-12 2018-11-06 Nordic Bioscience A/S Traitement du diabete et du syndrome metabolique
CA2802184C (fr) 2010-06-09 2019-01-08 Emisphere Technologies, Inc. Therapie orale de la carence en fer
JP5902194B2 (ja) 2010-12-16 2016-04-13 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
ES2612278T3 (es) 2011-04-12 2017-05-16 Novo Nordisk A/S Derivados de GLP-1 doble-acilados
JP6356660B2 (ja) 2012-03-22 2018-07-11 ノヴォ ノルディスク アー／エス 送達剤を含む組成物およびその調製
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
ES2952874T3 (es) 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
MY189670A (en) * 2015-07-08 2022-02-24 Research & Business Found Sungkyunkwan Univ Pyrrolidine carboxamido derivatives and methods for preparing and using the same
EA036204B1 (ru) * 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
CN107080739A (zh) * 2017-04-17 2017-08-22 深圳市泛谷药业股份有限公司 一种用于口服给药的固体快速释放布南色林片及其制备方法
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
JP2021054781A (ja) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド 共結晶形エフィナコナゾール、及びその製造方法
KR102301743B1 (ko) * 2020-12-29 2021-09-13 대봉엘에스 주식회사 에피나코나졸 경구용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015633A (en) 1987-04-27 1991-05-14 E. R. Squibb & Sons, Inc. Method for inhibiting loss of cognitive functions employing an ace inhibitor
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5002771A (en) 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
IT1238072B (it) 1990-01-19 1993-07-03 Sclavo Spa Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
JPH052771A (ja) * 1991-06-25 1993-01-08 Pioneer Electron Corp 光記録媒体
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
ATE199495T1 (de) 1994-12-14 2001-03-15 Enbalt Trading Ltd Pharmazeutische zubereitung zur direktverpressung
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5958453A (en) 1996-10-31 1999-09-28 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
EP1015008B1 (fr) 1997-02-07 2015-08-05 Emisphere Technologies, Inc. Composes et compositions destines a l'administration d'agents actifs
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
KR100620338B1 (ko) 1998-03-16 2006-09-13 넥타르 테라퓨틱스 에어로졸형 활성 제제 전달 방법
WO2000057857A1 (fr) 1999-03-25 2000-10-05 Yuhan Corporation Comprimé à administrer oralement se désagrégeant rapidement
EP1175390B1 (fr) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Sels disodiques, monohydrates et solvates ethanol pour liberer des agents actifs
WO2000059480A1 (fr) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Formes posologiques solides lyophylisees et procedes de fabrication

Also Published As

Publication number Publication date
HUP0302319A2 (hu) 2003-11-28
AU2002234547B2 (en) 2005-03-24
JP2009185052A (ja) 2009-08-20
CZ305418B6 (cs) 2015-09-09
US20020123459A1 (en) 2002-09-05
US7049283B2 (en) 2006-05-23
SK6882003A3 (en) 2004-01-08
PL362247A1 (en) 2004-10-18
HU230632B1 (hu) 2017-05-29
KR20040018309A (ko) 2004-03-03
PL209703B1 (pl) 2011-10-31
ZA200304295B (en) 2004-05-10
JP2004515480A (ja) 2004-05-27
CA2436599C (fr) 2011-01-25
EP1341526A2 (fr) 2003-09-10
JP4898078B2 (ja) 2012-03-14
WO2002045754A2 (fr) 2002-06-13
IL155992A (en) 2008-04-13
AU3454702A (en) 2002-06-18
BR0115965A (pt) 2003-10-28
CY1112562T1 (el) 2016-02-10
CA2436599A1 (fr) 2002-06-13
ATE513541T1 (de) 2011-07-15
NO332936B1 (no) 2013-02-04
SK287613B6 (sk) 2011-04-05
CN1479612A (zh) 2004-03-03
DK1341526T3 (da) 2011-10-03
EP1341526B1 (fr) 2011-06-22
NO20032511D0 (no) 2003-06-03
BRPI0115965B1 (pt) 2017-09-26
ECSP034639A (es) 2003-07-25
NZ526196A (en) 2005-01-28
WO2002045754A3 (fr) 2003-01-03
KR100847695B1 (ko) 2008-07-23
PT1341526E (pt) 2011-09-01
HK1059565A1 (en) 2004-07-09
HUP0302319A3 (en) 2013-04-29
RU2287999C2 (ru) 2006-11-27
CZ20031566A3 (cs) 2003-09-17
MXPA03005096A (es) 2003-09-05
ES2367009T3 (es) 2011-10-27
SI1341526T1 (sl) 2011-10-28
NO20032511L (no) 2003-06-03
CN1304048C (zh) 2007-03-14

Similar Documents

Publication Publication Date Title
AU3454702A (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents
HK1089950A1 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
ITMI20001173A0 (it) Composizioni farmaceutiche a rilascio prolungato per la somministrazione parenterale di sostanze idrofile biologicamente attiva.
PL348734A1 (en) New sustained release oral formulations
IL166561A0 (en) Pharmaceutical compositions
GEP20074047B (en) Pramipexole once-daily dosage form
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
NZ527157A (en) Compositions for delivering bisphosphonates
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
EP1392241A4 (fr) Systeme d'administration osmotique d'agents pharmaceutiquement actifs
MXPA03010761A (es) Combinaciones farmaceuticas.
IL151909A0 (en) Peptide conjugates for drug delivery
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
IL157540A0 (en) N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
WO2003041656A3 (fr) Systeme de liberation prolongee de medicaments solubles
HUP0303860A3 (en) A pharmaceutical tablet having a high active ingredient
MY128759A (en) Oral controlled release formulations
MY136370A (en) Oxazolidinone tablet formulation
MXPA01008348A (es) Microcapsulas para la liberacion prolongada de farmacos.
AU5654701A (en) Drug delivery mask
DE69904020D1 (de) Pharmazeutische zusammensetzung zur nasalen verabreichung von thiocolchicosid

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed